328 related articles for article (PubMed ID: 27307735)
1. Ethyl cellulose nanoparticles as a platform to decrease ulcerogenic potential of piroxicam: formulation and in vitro/in vivo evaluation.
El-Habashy SE; Allam AN; El-Kamel AH
Int J Nanomedicine; 2016; 11():2369-80. PubMed ID: 27307735
[TBL] [Abstract][Full Text] [Related]
2. Formulation strategy and evaluation of nanocrystal piroxicam orally disintegrating tablets manufacturing by freeze-drying.
Lai F; Pini E; Corrias F; Perricci J; Manconi M; Fadda AM; Sinico C
Int J Pharm; 2014 Jun; 467(1-2):27-33. PubMed ID: 24680963
[TBL] [Abstract][Full Text] [Related]
3. Preparation and evaluation of solid dispersions of piroxicam and Eudragit S100 by spherical crystallization technique.
Maghsoodi M; Sadeghpoor F
Drug Dev Ind Pharm; 2010 Aug; 36(8):917-25. PubMed ID: 20180658
[TBL] [Abstract][Full Text] [Related]
4. Preparation and characterization of novel anti-inflammatory biological agents based on piroxicam-loaded poly-ε-caprolactone nano-particles for sustained NSAID delivery.
Rahmani Del Bakhshayesh A; Akbarzadeh A; Alihemmati A; Tayefi Nasrabadi H; Montaseri A; Davaran S; Abedelahi A
Drug Deliv; 2020 Dec; 27(1):269-282. PubMed ID: 32009480
[TBL] [Abstract][Full Text] [Related]
5. Dissolution, bioavailability and ulcerogenic studies on piroxicam-nicotinamide solid dispersion formulations.
Verma MM; Kumar MT; Balasubramaniam J; Pandit JK
Boll Chim Farm; 2003 Apr; 142(3):119-24. PubMed ID: 12806831
[TBL] [Abstract][Full Text] [Related]
6. Formulation and biopharmaceutical evaluation of risperidone-loaded chitosan nanoparticles for intranasal delivery.
Rukmangathen R; Yallamalli IM; Yalavarthi PR
Drug Dev Ind Pharm; 2019 Aug; 45(8):1342-1350. PubMed ID: 31094571
[No Abstract] [Full Text] [Related]
7. Enhancement of solubility, dissolution release profile and reduction in ulcerogenicity of piroxicam by inclusion complex with skimmed milk.
Sanka K; Munjulury VS; Mohd AB; Diwan PV
Drug Deliv; 2014 Nov; 21(7):560-70. PubMed ID: 24266528
[TBL] [Abstract][Full Text] [Related]
8. Development of zolmitriptan loaded PLGA/poloxamer nanoparticles for migraine using quality by design approach.
Girotra P; Singh SK; Kumar G
Int J Biol Macromol; 2016 Apr; 85():92-101. PubMed ID: 26724690
[TBL] [Abstract][Full Text] [Related]
9. Nanocrystals as tool to improve piroxicam dissolution rate in novel orally disintegrating tablets.
Lai F; Pini E; Angioni G; Manca ML; Perricci J; Sinico C; Fadda AM
Eur J Pharm Biopharm; 2011 Nov; 79(3):552-8. PubMed ID: 21820052
[TBL] [Abstract][Full Text] [Related]
10. Enhanced anticancer activity and oral bioavailability of ellagic acid through encapsulation in biodegradable polymeric nanoparticles.
Mady FM; Shaker MA
Int J Nanomedicine; 2017; 12():7405-7417. PubMed ID: 29066891
[TBL] [Abstract][Full Text] [Related]
11. Chitosan-TPP nanoparticles stabilized by poloxamer for controlling the release and enhancing the bioavailability of doxazosin mesylate:
Aljaeid BM; El-Say KM; Hosny KM
Drug Dev Ind Pharm; 2019 Jul; 45(7):1130-1139. PubMed ID: 30884977
[No Abstract] [Full Text] [Related]
12. Amphotericin B loaded ethyl cellulose nanoparticles with magnified oral bioavailability for safe and effective treatment of fungal infection.
Kaur K; Kumar P; Kush P
Biomed Pharmacother; 2020 Aug; 128():110297. PubMed ID: 32480227
[TBL] [Abstract][Full Text] [Related]
13. Nanoemulsifying drug delivery system to improve the bioavailability of piroxicam.
Motawea A; Borg T; Tarshoby M; Abd El-Gawad AE
Pharm Dev Technol; 2017 May; 22(3):445-456. PubMed ID: 27583581
[TBL] [Abstract][Full Text] [Related]
14. Piroxicam nanoparticles for ocular delivery: physicochemical characterization and implementation in endotoxin-induced uveitis.
Adibkia K; Siahi Shadbad MR; Nokhodchi A; Javadzedeh A; Barzegar-Jalali M; Barar J; Mohammadi G; Omidi Y
J Drug Target; 2007 Jul; 15(6):407-16. PubMed ID: 17613659
[TBL] [Abstract][Full Text] [Related]
15. Increased localized delivery of piroxicam by cationic nanoparticles after intra-articular injection.
Kim SR; Ho MJ; Kim SH; Cho HR; Kim HS; Choi YS; Choi YW; Kang MJ
Drug Des Devel Ther; 2016; 10():3779-3787. PubMed ID: 27895468
[TBL] [Abstract][Full Text] [Related]
16. Alginate coated chitosan core shell nanoparticles for oral delivery of enoxaparin: in vitro and in vivo assessment.
Bagre AP; Jain K; Jain NK
Int J Pharm; 2013 Nov; 456(1):31-40. PubMed ID: 23994363
[TBL] [Abstract][Full Text] [Related]
17. Box-Behnken optimization design and enhanced oral bioavailability of thymopentin-loaded poly (butyl cyanoacrylate) nanoparticles.
Jin X; Huang A; Ping Q; Cao F; Su Z
Pharmazie; 2011 May; 66(5):339-47. PubMed ID: 21699067
[TBL] [Abstract][Full Text] [Related]
18. Preparation and evaluation of nimesulide-loaded ethylcellulose and methylcellulose nanoparticles and microparticles for oral delivery.
Ravikumara NR; Madhusudhan B; Nagaraj TS; Hiremat SR; Raina G
J Biomater Appl; 2009 Jul; 24(1):47-64. PubMed ID: 19386664
[TBL] [Abstract][Full Text] [Related]
19. Mucopenetrating nanoparticles for enhancement of oral bioavailability of furosemide: In vitro and in vivo evaluation/sub-acute toxicity study.
Radwan SE; Sokar MS; Abdelmonsif DA; El-Kamel AH
Int J Pharm; 2017 Jun; 526(1-2):366-379. PubMed ID: 28487189
[TBL] [Abstract][Full Text] [Related]
20. Rheological characterization and in vivo evaluation of thermosensitive poloxamer-based hydrogel for intramuscular injection of piroxicam.
Xuan JJ; Balakrishnan P; Oh DH; Yeo WH; Park SM; Yong CS; Choi HG
Int J Pharm; 2010 Aug; 395(1-2):317-23. PubMed ID: 20573569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
